Meng Xue1,2, San Chuan Lai2,3, Zhi Peng Xu1, Liang Jing Wang1,2. 1. Department of Gastroenterology, The Second Affiliated Hospital, School of Medicine, Zhejiang University. 2. Institute of Gastroenterology, Zhejiang University. 3. Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.
Abstract
OBJECTIVE: To summarize the current evidence on the biomarkers associated with DNA methylation in the screening and diagnosis of colorectal cancer (CRC). METHODS: A literature search was conducted on the databases of PubMed and Web of Science to identify articles published from 1 January 2000 to 6 June 2015 with language striction. Stuides focusing on the association between noninvasive biomarkers indicating DNA methylation and CRC were included. RESULTS: Altogether 74 studies were finally included in the study. Varied genetic markers in the feces and blood samples were hypermethylated in patients with CRC than in the healthy controls. Some of them could even be detected at the early stage of the tumors. The sensitivity of the genetic markers was superior to that of fecal occult blood test and carcinoembryonic antigen. Multitarget DNA assays using a combination of different methylated genes could improve the diagnostic sensitivity. CONCLUSIONS: Genetic markers might be minimally invasive, economical and accurate for the screening and surveillance of CRC. Large multicenter studies evaluating these biomarkers systematically and prospectively not only in CRC but also in other types of cancers are needed in the future.
OBJECTIVE: To summarize the current evidence on the biomarkers associated with DNA methylation in the screening and diagnosis of colorectal cancer (CRC). METHODS: A literature search was conducted on the databases of PubMed and Web of Science to identify articles published from 1 January 2000 to 6 June 2015 with language striction. Stuides focusing on the association between noninvasive biomarkers indicating DNA methylation and CRC were included. RESULTS: Altogether 74 studies were finally included in the study. Varied genetic markers in the feces and blood samples were hypermethylated in patients with CRC than in the healthy controls. Some of them could even be detected at the early stage of the tumors. The sensitivity of the genetic markers was superior to that of fecal occult blood test and carcinoembryonic antigen. Multitarget DNA assays using a combination of different methylated genes could improve the diagnostic sensitivity. CONCLUSIONS: Genetic markers might be minimally invasive, economical and accurate for the screening and surveillance of CRC. Large multicenter studies evaluating these biomarkers systematically and prospectively not only in CRC but also in other types of cancers are needed in the future.
Authors: Andrea Sartore-Bianchi; Federica Di Nicolantonio; Ludovic Barault; Alessio Amatu; Giulia Siravegna; Agostino Ponzetti; Sebastian Moran; Andrea Cassingena; Benedetta Mussolin; Chiara Falcomatà; Alexandra M Binder; Carmen Cristiano; Daniele Oddo; Simonetta Guarrera; Carlotta Cancelliere; Sara Bustreo; Katia Bencardino; Sean Maden; Alice Vanzati; Patrizia Zavattari; Giuseppe Matullo; Mauro Truini; William M Grady; Patrizia Racca; Karin B Michels; Salvatore Siena; Manel Esteller; Alberto Bardelli Journal: Gut Date: 2017-10-05 Impact factor: 23.059
Authors: Susan M Mitchell; Thu Ho; Glenn S Brown; Rohan T Baker; Melissa L Thomas; Aidan McEvoy; Zheng-Zhou Xu; Jason P Ross; Trevor J Lockett; Graeme P Young; Lawrence C LaPointe; Susanne K Pedersen; Peter L Molloy Journal: Genes (Basel) Date: 2016-12-15 Impact factor: 4.096
Authors: Hugo Sanchez; Mohammad B Hossain; Lydia Lera; Sandra Hirsch; Cecilia Albala; Ricardo Uauy; Karin Broberg; Ana M Ronco Journal: Clin Epigenetics Date: 2017-07-24 Impact factor: 6.551